Source:http://linkedlifedata.com/resource/pubmed/id/21402693
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
18
|
pubmed:dateCreated |
2011-5-2
|
pubmed:abstractText |
Abnormal vascular smooth muscle cell (VSMC) proliferation contributes to occlusive and proliferative disorders of the vessel wall. Salicylate and other nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit VSMC proliferation by an unknown mechanism unrelated to anti-inflammatory activity. In search for this mechanism, we have studied the effects of salicylate and other NSAIDs on subcellular Ca(2+) homeostasis and Ca(2+)-dependent cell proliferation in rat aortic A10 cells, a model of neointimal VSMCs. We found that A10 cells displayed both store-operated Ca(2+) entry (SOCE) and voltage-operated Ca(2+) entry (VOCE), the former being more important quantitatively than the latter. Inhibition of SOCE by specific Ca(2+) released-activated Ca(2+) (CRAC/Orai) channels antagonists prevented A10 cell proliferation. Salicylate and other NSAIDs, including ibuprofen, indomethacin, and sulindac, inhibited SOCE and thereby Ca(2+)-dependent, A10 cell proliferation. SOCE, but not VOCE, induced mitochondrial Ca(2+) uptake in A10 cells, and mitochondrial depolarization prevented SOCE, thus suggesting that mitochondrial Ca(2+) uptake controls SOCE (but not VOCE) in A10 cells. NSAIDs depolarized mitochondria and prevented mitochondrial Ca(2+) uptake, suggesting that they favor the Ca(2+)-dependent inactivation of CRAC/Orai channels. NSAIDs also inhibited SOCE in rat basophilic leukemia cells where mitochondrial control of CRAC/Orai is well established. NSAIDs accelerate slow inactivation of CRAC currents in rat basophilic leukemia cells under weak Ca(2+) buffering conditions but not in strong Ca(2+) buffer, thus excluding that NSAIDs inhibit SOCE directly. Taken together, our results indicate that NSAIDs inhibit VSMC proliferation by facilitating the Ca(2+)-dependent inactivation of CRAC/Orai channels which normally is prevented by mitochondria clearing of entering Ca(2+).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1083-351X
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
6
|
pubmed:volume |
286
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
16186-96
|
pubmed:meshHeading |
pubmed-meshheading:21402693-Animals,
pubmed-meshheading:21402693-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:21402693-Calcium,
pubmed-meshheading:21402693-Calcium Channels,
pubmed-meshheading:21402693-Cell Line, Tumor,
pubmed-meshheading:21402693-Cell Proliferation,
pubmed-meshheading:21402693-Ion Channel Gating,
pubmed-meshheading:21402693-Membrane Potential, Mitochondrial,
pubmed-meshheading:21402693-Mitochondria, Muscle,
pubmed-meshheading:21402693-Myocytes, Smooth Muscle,
pubmed-meshheading:21402693-Rats,
pubmed-meshheading:21402693-Vascular Diseases
|
pubmed:year |
2011
|
pubmed:articleTitle |
Nonsteroidal anti-inflammatory drugs inhibit vascular smooth muscle cell proliferation by enabling the Ca2+-dependent inactivation of calcium release-activated calcium/orai channels normally prevented by mitochondria.
|
pubmed:affiliation |
Institute of Molecular Biology and Genetics, University of Valladolid and Spanish Research Council, Valladolid, Spain.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|